Melanoma is characterised by its ability to metastasise at early stages of tumour
development. Current clinico‐pathologic staging based on the American Joint Committee on …

Importance The performance of prognostic gene expression profile (GEP) tests for
cutaneous melanoma is poorly characterized. Objective To systematically assess the …

The incidence of primary cutaneous melanoma continues to increase each year. Melanoma
accounts for the majority of skin cancer–related deaths, but treatment is usually curative …

The incidence of primary cutaneous melanoma has been increasing dramatically for several
decades. Melanoma accounts for the majority of skin cancer–related deaths, but treatment is …

Background Patients with high-risk stage II/III resected melanoma commonly develop distant
metastases. At present, we cannot differentiate between patients who will recur or those who …

Purpose: Biomarkers for disease-specific survival (DSS) in early-stage melanoma are
needed to select patients for adjuvant immunotherapy and accelerate clinical trial design …

Background The heterogeneous behavior of patients with melanoma makes prognostication
challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk …

Background Clinical and histopathologic assessment of pigmented skin lesions remains
challenging even for experts. Differentiated and accurate noninvasive diagnostic modalities …

PURPOSE National guidelines recommend sentinel lymph node biopsy (SLNB) be offered
to patients with> 10% likelihood of sentinel lymph node (SLN) positivity. On the other hand …

Background Multiple studies have reported on the accuracy of the prognostic 31-gene
expression profile test for cutaneous melanoma. Consistency of the test results across …